What happened after the clinical trials: Long-term safety and efficacy of ustekinumab in daily clinical practice

Dermatology

Volumn 229, Issue 4, 2014, Pages 324-332

  Talamonti, Marina ^a   Galluzzo, Marco ^a   Bianchi, Luca ^a   Boca, Andreea N ^b   Costanzo, Antonio ^c   Chimenti, Sergio ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Biologics; Clinical trials; Psoriasis; Real life; Tumor necrosis factor inhibitor; Ustekinumab

Indexed keywords

ADALIMUMAB; CYCLOSPORIN A; EFALIZUMAB; ETANERCEPT; ETRETIN; INFLIXIMAB; METHOTREXATE; PSORALEN; USTEKINUMAB; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT;

ADD ON THERAPY; ADULT; AGED; ARTICLE; ASTHENIA; BIOLOGICAL THERAPY; BODY MASS; BODY SURFACE; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); DISEASE DURATION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HERPES ZOSTER; HUMAN; HYPERHIDROSIS; JOINT SWELLING; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; METATARSOPHALANGEAL JOINT; PHARYNGITIS; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; RHINITIS; SYSTEMIC THERAPY; TREATMENT DURATION; TREATMENT RESPONSE; TUBERCULOSIS; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION; BODY WEIGHT; DRUG TOLERANCE; MIDDLE AGED; PSORIASIS; SEVERITY OF ILLNESS INDEX; TIME; YOUNG ADULT;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BODY WEIGHT; DRUG TOLERANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; PSORIASIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; YOUNG ADULT;

EID: 84929519464     PISSN: 10188665     EISSN: 14219832     Source Type: Journal    
DOI: 10.1159/000365077     Document Type: Article

References (30)

1. Lebwohl M: Psoriasis. Lancet 2003; 361:1197-1204.
2. Nickoloff BJ, Qin JZ, Nestle FO: Immuno-pathogenesis of psoriasis. Clin Rev Allergy Immunol 2007; 33:45-56.
3. Bowcock AM, Krueger JG: Getting under the skin: the immunogenetics of psoriasis. Nat Rev Immunol 2005; 5:699-711.
4. Griffiths CE, Barker JN: Pathogenesis and clinical features of psoriasis. Lancet 2007; 370: 263-271.
5. Lowes MA, Bowcock AM, Krueger JG: Patho-genesis and therapy of psoriasis. Nature 2007; 445:866-873.
6. Talamonti M, Botti E, Galluzzo M, Teoli M, Spallone G, Bavetta M, Chimenti S, Costanzo A: Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinu-mab. Br J Dermatol 2013; 169: 458-463.
7. Blauvelt A: T-helper 17 cells in psoriatic plaques and additional genetic links between IL-23 and psoriasis. J Invest Dermatol 2008; 128:1064-1067.
8. Toussirot E: The IL-23/Th17 pathway as a therapeutic target in chronic inflammatory diseases. Inflamm Allergy Drug Targets 2012; 11:159-168.
9. Sandborn WJ, Feagan BG, Fedorak RN, Scherl E, Fleisher MR, Katz S: A randomized trial of ustekinumab, a human interleu-kin-12/23 monoclonal antibody in patients with moderate to severe Crohn's disease. Gas-troenterology 2008; 135:1130-1141.
10. Sandborn WJ, Gasink C, Gao LL, Blank MA, Johanns J, Guzzo C, Sands BE, Hanauer SB, Targan S, Rutgeerts P, Ghosh S, de Villiers WJ, Panaccione R, Greenberg G, Schreiber S, Lichtiger S, Feagan BG; CERTIFI Study Group: Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med 2012; 367:1519-1528.
11. Croxtall JD: Ustekinumab: a review of its use in the management of moderate to severe plaque psoriasis. Drugs 2011; 71:1733-1753.
12. Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, Li S, Dooley LT, Gordon KB; PHOENIX 1 study investigators: Efficacy and safety of ustekinumab, a human interleu-kin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371:1665-1674.
13. Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, Guzzo C, Hsu MC, Wang Y, Li S, Dooley LT, Reich K; PHOENIX 2 study investigators: Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371:1675-1684.
14. Griffiths CE, Strober BE, van de Kerkhof P, Ho V, Fidelus-Gort R, Yeilding N, Guzzo C, Xia Y, Zhou B, Li S, Dooley LT, Goldstein NH, Menter A; ACCEPT Study Group: Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010; 362:118-128.
15. Gottlieb A, Narang K: Ustekinumab in the treatment of psoriatic arthritis: latest findings and clinical potential. Ther Adv Musculo-skelet Dis 2013; 5:277-285.
16. McInnes IB, Kavanaugh A, Gottlieb AB, Puig L, Rahman P, Ritchlin C, Brodmerkel C, Li S, Wang Y, Mendelsohn AM, Doyle MK; PSUMMIT 1 Study Group: Efficacy and safety of ustekinumab in patients with active pso-riatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 2013; 382: 780-789.
17. Ritchlin CT, Gottlieb AB, McInnes IB, Puig L, Rahman P, Li S, Wang Y: Ustekinumab in active psoriatic arthritis including patients previously treated with anti-TNF agents: results of a phase 3, multicenter, double-blind, placebo controlled study. Arthritis Rheum 2012; 64(suppl 10):S1080-S1081.
18. Puig L, Ruiz-Salas V: Long-term efficacy, safety and drug survival of ustekinumab in a Spanish cohort of patients with moderate to severe plaque psoriasis. Dermatology, in press.
19. Laws PM, Downs AM, Parslew R, Dever B, Smith CH, Barker JN, Moriarty B, Murphy R, Kirby B, Burden AD, McBride S, Anstey AV, O'Shea S, Ralph N, Buckley C, Griffiths CE, Warren RB: Practical experience of usteki-numab in the treatment of psoriasis: experience from a multicentre, retrospective case cohort study across the UK and Ireland. Br J Dermatol 2012; 166:189-195.
20. Papp KA, Strober B, Augustin M, Calabro S, Londhe A, Chevrier M; PSOLAR Investigators and Steering Committee: PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents. J Drugs Dermatol 2012; 11:1210-1217.
21. Burden AD, Warren RB, Kleyn CE, McEl-hone K, Smith CH, Reynolds NJ, Ormerod AD, Griffiths CE; BADBIR Study Group: The British Association of Dermatologists' Biologic Interventions Register (BADBIR): design, methodology and objectives. Br J Der-matol 2012; 166:545-554.
22. Brass EP: The gap between clinical trials and clinical practice: the use of pragmatic clinical trials to inform regulatory decision making. Clin Pharmacol Ther 2010; 87:351-355.
23. Finlay AY: Current severe psoriasis and the rule of tens. Br J Dermatol 2005; 152:861-867.
24. Fairhurst DA, Ashcroft DM, Griffiths CE: Optimal management of severe plaque form of psoriasis. Am J Clin Dermatol 2005; 6: 283-294.
25. Yeung H, Wan J, Van Voorhees AS, Callis Duffin K, Krueger GG, Kalb RE, Weisman JD, Sperber BR, Brod BA, Schleicher SM, Bebo BF Jr, Shin DB, Troxel AB, Gelfand JM: Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis. J Am Acad Dermatol 2013; 68:64-72.
26. Hyrich KL, Symmons DP, Silman AJ; OMER-ACT 7 Special Interest Group: Reconciling subject differences in recruitment to clinical trials and clinical practice. J Rheumatol 2005; 32:2475-2476.
27. Papp KA, Griffiths CE, Gordon K, Lebwohl M, Szapary PO, Wasfi Y, Chan D, Hsu MC, Ho V, Ghislain PD, Strober B, Reich K; PHOENIX 1 Investigators; PHOENIX 2 Investigators; ACCEPT Investigators: Longterm safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol 2013; 168:844-854.
28. Kimball AB, Papp KA, Wasfi Y, Chan D, Bis-sonnette R, Sofen H, Yeilding N, Li S, Sza-pary P, Gordon KB; PHOENIX 1 Investigators: Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. J Eur Acad Dermatol Venereol 2013; 27:1535-1545.
29. Berth-Jones J, Thompson J, Papp K; Copenhagen Psoriasis Working Group: A study examining interrater and intrarater reliability of a novel instrument for assessment of psoriasis: the Copenhagen Psoriasis Severity Index. Br J Dermatol 2008; 159:407-412.
30. Puig L, Roé E, García-Navarro X, Corella F, Alomar A: Efalizumab treatment of psoriasis vulgaris: a cohort study in outpatient clinical practice. Clin Exp Dermatol 2009; 34: 469-475.